Videos

CORE-008 Trial TT

CORE-008 Cohort B Tests Cretostimogene’s Efficacy in High-Risk, Non-BCG-Responsive Disease - Trinity Bivalacqua Details Zachary Klaassen and Trinity Bivalacqua discuss Cohort B of the CORE-008 trial, which examines cretostimogene in BCG-exposed patients with high-risk non-muscle invasive bladder cancer. The phase 2 multi-cohort, multicenter study focuses on patients who have recurrent high-grade disease but do not meet BCG-unresponsive criteria. The treatment protocol includes a six-week induction course of cretost...
CORE-008 Cohort A Tests Oncolytic Immunotherapy in BCG-Naive High-Risk Bladder Cancer - Trinity Bivalacqua Details Trinity Bivalacqua joins Zachary Klaasen to discuss the CORE-008 trial, specifically focusing on cohort A, which examines cretostimogene in high-risk, non-muscle-invasive bladder cancer. The conversation explores this phase II multi-cohort, multicenter, open-label study that targets BCG-naive patients with CIS, with or without papillary disease. The treatment protocol involves a six-week induction...